Clinical trials: copd or chronic obstructive
Infection, Pulmonary Disease, Chronic Obstructive
Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients.
- Trial name
- NCT01168895
- Testing
- Cipro Inhale (Ciprofloxacin, BAYQ3939)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the…
- Trial name
- NCT00528996
- Testing
- BEA 2180 BR, Tiotropium Bromide
- Where
- 178 sites in United States, Canada and 8 more
- Volunteers
- 2,080 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT02119286
- Testing
- FF, VI, UMEC
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 620 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
- Trial name
- NCT01089127
- Testing
- Indacaterol, Salmeterol 50 μg
- Where
- 69 sites in United States
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
- Trial name
- NCT04169529
- Testing
- Reveal LINQ
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Disease, Chronic Obstructive
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese…
- Trial name
- NCT01703845
- Testing
- Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
The prevalence, low cost, and low burden of wearable devices that provide quantitative and qualitative feedback on a subject's activity level present an opportunity for the use of these devices in clinical and observational…
- Trial name
- NCT02619357
- Testing
- SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01322594
- Testing
- MEDI2338
- Where
- 4 sites in South Africa, United Kingdom
- Volunteers
- 31 people
- Sponsor
- MedImmune LLC
COPD
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease
This is a 26 week randomized controlled study. The study consists of, in order, an enrollment visit, followed by clinic visits at 2 weeks, 14 weeks and at 26 weeks.
- Trial name
- NCT01186822
- Testing
- Lung Flute
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Nicolaas J Smit PhD
GVHD, Chronic
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2.
- Trial name
- NCT06169722
- Testing
- TDI01 suspension
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Breathing-Related Sleep Disorder
A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD
This is a multicenter, randomized, parallel-group, open label study of the efficacy of AVAPS-AE to prevent re-hospitalization in hospitalized patients with comorbid Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- STOP-BBACK (NCT02446769)
- Testing
- AVAPS-AE Non-invasive ventilation therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Philips Respironics
Chronic Obstructive Pulmonary Disease
AZD9668 Relative Bioavailability
The study is designed to investigate the pharmacokinetic behaviour of the free base formulation of AZD9668. The study will compared the relative bioavailability of the free base formulation at two different dose levels compared…
- Trial name
- NCT01034982
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in…
- Trial name
- NCT07288554
- Testing
- BBT002
- Where
- 11 sites in China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
This was an exploratory, randomized, subject- and investigator-blind, placebo-controlled, parallel group, proof-of-mechanism study of multiple oral doses of fevipiprant (QAW039) in chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03810183
- Testing
- QAW039
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65…
- Conditions
- Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
- Trial name
- NCT04647383
- Testing
- Lemborexant 10 mg
- Where
- 11 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Pulmonary Disease, Chronic Obstructive
Sensor and Electronic Health Records (EHR) Integration Pilot Study
This is a pilot study that will evaluate the feasibility of collecting increasing amounts of clinical study data from subjects through sensor and web/app based methods and integrating it with data from their EHR to facilitate…
- Trial name
- NCT03357341
- Testing
- Mobile spirometer, Device sensor, Salbutamol
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- GlaxoSmithKline
COPD Patients With Homogeneous Emphysema, Endoscopic Lung Volume Reduction With Endobronchial Valve
Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study
The aim of this prospective, randomized, controlled, one-way crossover study is to assess and compare the efficacy of the Zephyr endobronchial valves vs.
- Trial name
- IMPACT (NCT02025205)
- Testing
- Endobronchial Valve
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 93 people
- Sponsor
- Pulmonx International Sàrl
COPD Exacerbation
Non-contact Proactive Remote Monitoring of COPD Exacerbations
The goal of this observational study is to determine if a COPD exacerbation can be detected early in its onset. The main questions it aims to answer are: Can an exacerbation be detected before the person recognizes they are…
- Trial name
- DetectEx (NCT05598983)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Life Detection Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.